help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carr, B. R.
Right arrow Articles by Marshburn, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carr, B. R.
Right arrow Articles by Marshburn, P. B.

Journal of Clinical Endocrinology & Metabolism, Vol 80, 1169-1178, Copyright © 1995 by Endocrine Society


ARTICLES

Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study

BR Carr, NA Breslau, C Givens, W Byrd, C Barnett-Hamm and PB Marshburn
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas 75235-9032, USA.

The effectiveness of oral contraceptive pills (OCPs), GnRH agonist (GnRH-a), and a combination of OCPs and GnRH-a in the treatment of hirsute women was compared and the impact of these treatments on hormonal and Ca metabolism was investigated. Thirty-three women were prospectively enrolled and randomized into three treatment groups (11 in each group). The serum levels of LH, estradiol, testosterone, free testosterone, androstenedione, and 17-hydroxyprogesterone declined in all 3 treatment groups, whereas the inclusion of GnRH-a treatment tended to promote a more rapid decrease in these hormone levels. Total cholesterol, low density lipoprotein, and high density lipoprotein levels remained unchanged. The assessment of hirsutism by the Ferriman- Gallwey score revealed a similar 25% reduction in score by all three treatment groups by 6 months. In addition, no difference was detected between groups with respect to hair diameters and the vellus index. Clinical assessment of hirsutism at 3 months by the patients revealed that the GnRH-a and the OCPs-plus-GnRH-a groups had better responses than the group on OCPs alone, but by 6 months all three groups were similar. The symptoms of hot flashes and vaginal dryness were greatest in subjects treated with GnRH-a alone. Serum Ca, phosphorus, alkaline phosphatase, osteocalcin, and 2-h fasting and 24-h urinary Ca excretion levels all increased significantly in subjects treated with the GnRH-a alone, whereas a decrement or no changes occurred for these measurement in the other two groups. The estimated Ca balance was unchanged in the OCPs and the OCPs-plus-GnRH-a groups but declined by 90 mg/day from baseline in the GnRH-a-treated women (p < or = 0.001). Bone density significantly decreased in the lumber spine in women treated with GnRH- a alone, with a less marked decline in the femoral neck. In contrast, women receiving OCPs plus GnRH had increased bone density in the lumbar spine. It is concluded that: 1) clinical measures of hirsutism are not different after 6 months of treatment with OCPs alone, GnRH-a alone, or a combination of the two; 2) the decline in gonadotropins and steroid hormones and improvement in clinical response were more rapid and pronounced when GnRH-a treatment was added to OCP administration; and 3) the negative impact of GnRH-a alone on Ca balance and bone loss limits its usefulness as a single agent for long-term therapy of hirsutism.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
K. A. Martin, R. J. Chang, D. A. Ehrmann, L. Ibanez, R. A. Lobo, R. L. Rosenfield, J. Shapiro, V. M. Montori, and B. A. Swiglo
Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1105 - 1120.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Beleza-Meireles, I. Kockum, F. Lundberg, C. Soderhall, and A. Nordenskjold
Risk Factors for Hypospadias in the Estrogen Receptor 2 Gene
J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3712 - 3718.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Hietala, T. Sandberg, A. Borg, H. Olsson, and H. Jernstrom
Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women
Hum. Reprod., January 1, 2007; 22(1): 83 - 91.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
J. Vrbikova and D. Cibula
Combined oral contraceptives in the treatment of polycystic ovary syndrome
Hum. Reprod. Update, May 1, 2005; 11(3): 277 - 291.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Westberg, F. Baghaei, R. Rosmond, M. Hellstrand, M. Landen, M. Jansson, G. Holm, P. Bjorntorp, and E. Eriksson
Polymorphisms of the Androgen Receptor Gene and the Estrogen Receptor {beta} Gene Are Associated with Androgen Levels in Women
J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2562 - 2568.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
M. J. Jayo, T. C. Register, C. L. Hughes, U. Blas-Machado, E. Sulistiawati, H. Borgerink, and C. S. Johnson
Effects of an Oral Contraceptive Combination With or Without Androgen on Mammary Tissues: A Study in Rats
Reproductive Sciences, July 1, 2000; 7(4): 257 - 265.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society